Format

Send to

Choose Destination
Immunol Res. 2014 Dec;60(2-3):219-25. doi: 10.1007/s12026-014-8574-4.

Evolution of multiple sclerosis in France since the beginning of hepatitis B vaccination.

Author information

1
REVAHB ("Réseau Vaccin Hépatite B" in French), 32 rue du Clos Herbert, 14000, Caen, France, dominique.le.houezec@freesbee.fr.

Abstract

Since the implementation of the mass vaccination campaign against hepatitis B in France, the appearance of multiple sclerosis, sometimes occurring in the aftermath of vaccinations, led to the publication of epidemiological international studies. This was also justified by the sharp increase in the annual incidence of multiple sclerosis reported to the French health insurance in the mid-1990s. Almost 20 years later, a retrospective reflection can be sketched from these official data and also from the national pharmacovigilance agency. Statistical data from these latter sources seem to show a significant correlation between the number of hepatitis B vaccinations performed and the declaration to the pharmacovigilance of multiple sclerosis occurring between 1 and 2 years later. The application of the Hill's criteria to these data indicates that the correlation between hepatitis B vaccine and multiple sclerosis may be causal.

PMID:
25395338
PMCID:
PMC4266455
DOI:
10.1007/s12026-014-8574-4
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center